Zhang Jian-wen, Li Yang, Zeng Xian-Cheng, Zhang Tong, Fu Bin-Sheng, Yi Hui-Min, Zhang Qi, Jiang Nan
Department of Hepatic Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland).
Department of General Surgery, Zengcheng People's Hospital, (BoJi-Affiliated Hospital of Sun Yat-Sen University), Zengcheng, Guangdong, China (mainland).
Med Sci Monit. 2015 Mar 3;21:667-73. doi: 10.12659/MSM.892515.
MicroRNA-630 (miR-630) has been shown to be involved in various human malignancies. However, its role in hepatocellular carcinoma (HCC) remains unknown.
TaqMan qRT-PCR assay was performed to detect the expression of miR-630 in 42 pairs of HCC tissues and corresponding noncancerous hepatocellular tissues, and its correlations with clinicopathologic features and serum alpha-fetoprotein (AFP) level of patients were analyzed.
The present study found that miR-630 expression was significantly increased in HCC tissues and cells compared with their normal counterparts. miR-630 expression level did not significantly chang at stage I but was markedly increased at advanced TNM stage (stage II~III). In addition, the increased expression of miR-630 in tissues of HCC appeared in patients who exhibited elevated serum levels of AFP (>25 ng/ml), but not in those with normal AFP levels (≤25 ng/ml). The miR-630 expression in carcinoma tissues revealed a positive correlation with the levels of serum alpha-fetoprotein (AFP; R2=0.768).
These results suggest that miR-630 is associated with tumor progression of hepatocellular carcinoma and may be a potential prognosis indicator.
微小RNA-630（miR-630）已被证明参与多种人类恶性肿瘤。然而，其在肝细胞癌（HCC）中的作用仍不清楚。
采用TaqMan qRT-PCR检测42对HCC组织及相应癌旁肝细胞组织中miR-630的表达，并分析其与患者临床病理特征及血清甲胎蛋白（AFP）水平的相关性。
本研究发现，与正常组织和细胞相比，miR-630在HCC组织和细胞中的表达显著增加。miR-630表达水平在I期无明显变化，但在TNM晚期（II~III期）显著升高。此外，血清AFP水平升高（>25 ng/ml）的HCC患者组织中miR-630表达增加，而AFP水平正常（≤25 ng/ml）的患者则无此现象。癌组织中miR-630表达与血清甲胎蛋白（AFP）水平呈正相关（R2=0.768）。
这些结果表明，miR-630与肝细胞癌的肿瘤进展相关，可能是一个潜在的预后指标。
